Mesoblast Limited logo

Mesoblast Limited

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company's lead product candidate is remestemcel-L, an allogeneic mesenchymal precursor cell therapy that has completed Phase III clinical trial for use in steroid-refractory acute graft versus host disease. It also developed MSC-100-IV that is in Phase II clinical trial to investigate its effects on preventing organ dysfunction and death; MPC-150-IM to treat chronic heart failure; and MPC-06-ID to treat chronic low back pain due to advanced degenerative disc disease. In addition, it has licensed RemestemcelTM to JCR Pharmaceuticals Co., Ltd.; RemestemcelTM-L to JCR Pharmaceuticals Co., Ltd.; revascorTM through a partnership agreement with Pfizer Inc.; and MPC-300-IV through Cytori Therapeutics Inc. The company was founded in 2004 and is headquartered in Melbourne, Australia.

Latest events on Quartr

Previous Events for Mesoblast Limited





About the company

Investor Relations page

Dig deeper into the fundamentals using Quartr - Investor relations

  • Skip straight to the Q&A session
  • Receive notifications about new events
  • Connect the financial calender on your phone
  • Figure out why the stock is up or down
  • Read the transcripts or scroll the deck
  • Access earnings or press releases
Android play link
App store link
Quartr app screenshot